Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC022F CAR-T for Relapsed/Refractory B-NHL
NCT04412174Phase 1Unknown
- Sponsor
- Lu Daopei Hospital
- Start
- Jun 2020
- Primary completion
- Dec 2022
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC022 in B-cell non-Hodgkin lymphoma, sponsored by Lu Daopei Hospital. Primary endpoints: Dose Limiting Toxicity at 2 years and Treatment Related Adverse Events at 2 years. Status: unknown.
02
Drugs
GC022
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04412174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04412174.